Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body鈥檚 innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.
Regenerative medicine is defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function and has been called the "next evolution of medical treatments" and 鈥渢he vanguard of 21st century healthcare鈥� by the U.S. Department of Health and Human Services.
The global market for Regenerative Medicine was estimated to be worth US$ 33370 million in 2023 and is forecast to a readjusted size of US$ 115660 million by 2030 with a CAGR of 19.2% during the forecast period 2024-2030
Global Regenerative Medicine key players include J & J (DePuy Synthes), Medtronic, Allergan(Acelity), Zimmer Biomet, etc. Global top four manufacturers hold a share about 10%.
North America is the largest market, with a share about 25%, followed by Europe, and Asia Pacific, both have a share over 40 percent.
In terms of product, Tissue Engineering is the largest segment, with a share over 40%. And in terms of application, the largest application is Dermatology, followed by Cardiovascular, CNS, Orthopedic, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Regenerative Medicine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Regenerative Medicine by region & country, by Type, and by Application.
The Regenerative Medicine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Regenerative Medicine.
麻豆原创 Segmentation
By Company
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering
Segment by Type:
Cell Therapy
Tissue Engineering
Biomaterial
Other
Segment by Application
Dermatology
Cardiovascular
CNS
Orthopedic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Regenerative Medicine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Regenerative Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Regenerative Medicine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Regenerative Medicine Product Introduction
1.2 Global Regenerative Medicine 麻豆原创 Size Forecast
1.3 Regenerative Medicine 麻豆原创 Trends & Drivers
1.3.1 Regenerative Medicine Industry Trends
1.3.2 Regenerative Medicine 麻豆原创 Drivers & Opportunity
1.3.3 Regenerative Medicine 麻豆原创 Challenges
1.3.4 Regenerative Medicine 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Regenerative Medicine Players Revenue Ranking (2023)
2.2 Global Regenerative Medicine Revenue by Company (2019-2024)
2.3 Key Companies Regenerative Medicine Manufacturing Base Distribution and Headquarters
2.4 Key Companies Regenerative Medicine Product Offered
2.5 Key Companies Time to Begin Mass Production of Regenerative Medicine
2.6 Regenerative Medicine 麻豆原创 Competitive Analysis
2.6.1 Regenerative Medicine 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Regenerative Medicine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Regenerative Medicine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cell Therapy
3.1.2 Tissue Engineering
3.1.3 Biomaterial
3.1.4 Other
3.2 Global Regenerative Medicine Sales Value by Type
3.2.1 Global Regenerative Medicine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Regenerative Medicine Sales Value, by Type (2019-2030)
3.2.3 Global Regenerative Medicine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Dermatology
4.1.2 Cardiovascular
4.1.3 CNS
4.1.4 Orthopedic
4.1.5 Others
4.2 Global Regenerative Medicine Sales Value by Application
4.2.1 Global Regenerative Medicine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Regenerative Medicine Sales Value, by Application (2019-2030)
4.2.3 Global Regenerative Medicine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Regenerative Medicine Sales Value by Region
5.1.1 Global Regenerative Medicine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Regenerative Medicine Sales Value by Region (2019-2024)
5.1.3 Global Regenerative Medicine Sales Value by Region (2025-2030)
5.1.4 Global Regenerative Medicine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Regenerative Medicine Sales Value, 2019-2030
5.2.2 North America Regenerative Medicine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Regenerative Medicine Sales Value, 2019-2030
5.3.2 Europe Regenerative Medicine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Regenerative Medicine Sales Value, 2019-2030
5.4.2 Asia Pacific Regenerative Medicine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Regenerative Medicine Sales Value, 2019-2030
5.5.2 South America Regenerative Medicine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Regenerative Medicine Sales Value, 2019-2030
5.6.2 Middle East & Africa Regenerative Medicine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Regenerative Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Regenerative Medicine Sales Value
6.3 United States
6.3.1 United States Regenerative Medicine Sales Value, 2019-2030
6.3.2 United States Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Regenerative Medicine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Regenerative Medicine Sales Value, 2019-2030
6.4.2 Europe Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Regenerative Medicine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Regenerative Medicine Sales Value, 2019-2030
6.5.2 China Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Regenerative Medicine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Regenerative Medicine Sales Value, 2019-2030
6.6.2 Japan Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Regenerative Medicine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Regenerative Medicine Sales Value, 2019-2030
6.7.2 South Korea Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Regenerative Medicine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Regenerative Medicine Sales Value, 2019-2030
6.8.2 Southeast Asia Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Regenerative Medicine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Regenerative Medicine Sales Value, 2019-2030
6.9.2 India Regenerative Medicine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Regenerative Medicine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 J & J (DePuy Synthes)
7.1.1 J & J (DePuy Synthes) Profile
7.1.2 J & J (DePuy Synthes) Main Business
7.1.3 J & J (DePuy Synthes) Regenerative Medicine Products, Services and Solutions
7.1.4 J & J (DePuy Synthes) Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.1.5 J & J (DePuy Synthes) Recent Developments
7.2 Medtronic
7.2.1 Medtronic Profile
7.2.2 Medtronic Main Business
7.2.3 Medtronic Regenerative Medicine Products, Services and Solutions
7.2.4 Medtronic Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.2.5 Medtronic Recent Developments
7.3 Zimmer Biomet
7.3.1 Zimmer Biomet Profile
7.3.2 Zimmer Biomet Main Business
7.3.3 Zimmer Biomet Regenerative Medicine Products, Services and Solutions
7.3.4 Zimmer Biomet Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.3.5 Stryker Recent Developments
7.4 Stryker
7.4.1 Stryker Profile
7.4.2 Stryker Main Business
7.4.3 Stryker Regenerative Medicine Products, Services and Solutions
7.4.4 Stryker Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.4.5 Stryker Recent Developments
7.5 Allergan(Acelity)
7.5.1 Allergan(Acelity) Profile
7.5.2 Allergan(Acelity) Main Business
7.5.3 Allergan(Acelity) Regenerative Medicine Products, Services and Solutions
7.5.4 Allergan(Acelity) Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.5.5 Allergan(Acelity) Recent Developments
7.6 MiMedx Group
7.6.1 MiMedx Group Profile
7.6.2 MiMedx Group Main Business
7.6.3 MiMedx Group Regenerative Medicine Products, Services and Solutions
7.6.4 MiMedx Group Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.6.5 MiMedx Group Recent Developments
7.7 Organogenesis
7.7.1 Organogenesis Profile
7.7.2 Organogenesis Main Business
7.7.3 Organogenesis Regenerative Medicine Products, Services and Solutions
7.7.4 Organogenesis Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.7.5 Organogenesis Recent Developments
7.8 Fujifilm Cellular Dynamics
7.8.1 Fujifilm Cellular Dynamics Profile
7.8.2 Fujifilm Cellular Dynamics Main Business
7.8.3 Fujifilm Cellular Dynamics Regenerative Medicine Products, Services and Solutions
7.8.4 Fujifilm Cellular Dynamics Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.8.5 Fujifilm Cellular Dynamics Recent Developments
7.9 Osiris Therapeutics
7.9.1 Osiris Therapeutics Profile
7.9.2 Osiris Therapeutics Main Business
7.9.3 Osiris Therapeutics Regenerative Medicine Products, Services and Solutions
7.9.4 Osiris Therapeutics Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.9.5 Osiris Therapeutics Recent Developments
7.10 Vcanbio
7.10.1 Vcanbio Profile
7.10.2 Vcanbio Main Business
7.10.3 Vcanbio Regenerative Medicine Products, Services and Solutions
7.10.4 Vcanbio Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.10.5 Vcanbio Recent Developments
7.11 CCBC
7.11.1 CCBC Profile
7.11.2 CCBC Main Business
7.11.3 CCBC Regenerative Medicine Products, Services and Solutions
7.11.4 CCBC Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.11.5 CCBC Recent Developments
7.12 Cytori
7.12.1 Cytori Profile
7.12.2 Cytori Main Business
7.12.3 Cytori Regenerative Medicine Products, Services and Solutions
7.12.4 Cytori Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.12.5 Cytori Recent Developments
7.13 Celgene
7.13.1 Celgene Profile
7.13.2 Celgene Main Business
7.13.3 Celgene Regenerative Medicine Products, Services and Solutions
7.13.4 Celgene Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.13.5 Celgene Recent Developments
7.14 Vericel Corporation
7.14.1 Vericel Corporation Profile
7.14.2 Vericel Corporation Main Business
7.14.3 Vericel Corporation Regenerative Medicine Products, Services and Solutions
7.14.4 Vericel Corporation Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.14.5 Vericel Corporation Recent Developments
7.15 Guanhao Biotech
7.15.1 Guanhao Biotech Profile
7.15.2 Guanhao Biotech Main Business
7.15.3 Guanhao Biotech Regenerative Medicine Products, Services and Solutions
7.15.4 Guanhao Biotech Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.15.5 Guanhao Biotech Recent Developments
7.16 Mesoblast
7.16.1 Mesoblast Profile
7.16.2 Mesoblast Main Business
7.16.3 Mesoblast Regenerative Medicine Products, Services and Solutions
7.16.4 Mesoblast Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.16.5 Mesoblast Recent Developments
7.17 AMAG Pharmaceuticals (CBR)
7.17.1 AMAG Pharmaceuticals (CBR) Profile
7.17.2 AMAG Pharmaceuticals (CBR) Main Business
7.17.3 AMAG Pharmaceuticals (CBR) Regenerative Medicine Products, Services and Solutions
7.17.4 AMAG Pharmaceuticals (CBR) Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.17.5 AMAG Pharmaceuticals (CBR) Recent Developments
7.18 ViaCord
7.18.1 ViaCord Profile
7.18.2 ViaCord Main Business
7.18.3 ViaCord Regenerative Medicine Products, Services and Solutions
7.18.4 ViaCord Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.18.5 ViaCord Recent Developments
7.19 CordLife
7.19.1 CordLife Profile
7.19.2 CordLife Main Business
7.19.3 CordLife Regenerative Medicine Products, Services and Solutions
7.19.4 CordLife Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.19.5 CordLife Recent Developments
7.20 Integra LifeSciences
7.20.1 Integra LifeSciences Profile
7.20.2 Integra LifeSciences Main Business
7.20.3 Integra LifeSciences Regenerative Medicine Products, Services and Solutions
7.20.4 Integra LifeSciences Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.20.5 Integra LifeSciences Recent Developments
7.21 Nuvasive
7.21.1 Nuvasive Profile
7.21.2 Nuvasive Main Business
7.21.3 Nuvasive Regenerative Medicine Products, Services and Solutions
7.21.4 Nuvasive Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.21.5 Nuvasive Recent Developments
7.22 Cook Biotech
7.22.1 Cook Biotech Profile
7.22.2 Cook Biotech Main Business
7.22.3 Cook Biotech Regenerative Medicine Products, Services and Solutions
7.22.4 Cook Biotech Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.22.5 Cook Biotech Recent Developments
7.23 Japan Tissue Engineering
7.23.1 Japan Tissue Engineering Profile
7.23.2 Japan Tissue Engineering Main Business
7.23.3 Japan Tissue Engineering Regenerative Medicine Products, Services and Solutions
7.23.4 Japan Tissue Engineering Regenerative Medicine Revenue (US$ Million) & (2019-2024)
7.23.5 Japan Tissue Engineering Recent Developments
8 Industry Chain Analysis
8.1 Regenerative Medicine Industrial Chain
8.2 Regenerative Medicine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Regenerative Medicine Sales Model
8.5.2 Sales Channel
8.5.3 Regenerative Medicine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering
听
听
*If Applicable.
